PD-1+ T cells trigger pulmonary fibrosis
A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1203 entries already.
Entries by Thomas Gabrielczyk
CRISPR-gene drive safely kills mosquitos
/in News/by Thomas GabrielczykA new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
CHMP with new Chair 13 meds recommended
/in News/by Thomas GabrielczykThe CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European biotech companies enter IPO prep course
/in News/by Thomas GabrielczykEuropean stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies this time also including companies from Germany, Italy, Spain, and Switzerland.
Novo Nordisk reveals details about its R&D transformation
/in News/by Thomas GabrielczykNovo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and […]
Pharming receives complete response letter from FDA
/in News/by Thomas GabrielczykThe FDA has requested additional clincal data demonstrating that Pharming Group’s recombinant C1 esterase blocker Ruconest can prevent hereditary angioedema attacks (HAE).
CRISPR Therapeutics and Viacyte launch diabetes partnership
/in News/by Thomas GabrielczykCRISPR Therapeutics AG announced a development partnership with ViaCyte Inc to develop genome-edited pancreatic islet cells, which do not require immunosuppression, to treat diabetes.
Sanofi preparing label extension for dupilumab
/in News/by Thomas GabrielczykPositive Phase 3 results with Sanofi/Regeneron’s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of […]
Calcium does not contribute to heart failure
/in News/by Thomas GabrielczykSlowing the leak of Calcium leak into cardiomyocytes does not improve the pumping malfunction in heart failure, German cardiologists report in Science Translational Medicine.
Boehringer Ingelheim bags ViraT in 210m deal
/in News/by Thomas GabrielczykEMBL Ventures has announced that its portfolio company ViraTherapeutics is set to be acquired by Boehringer Ingelheim in a 210m million (US$245m) transaction.